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Abstract
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Our group recently identified a panel of ten genes whose RNA expression levels in whole blood
have utility for detection of stroke. The purpose of this study was to determine the mechanisms by
which these genes become differentially expressed during stroke pathology. First, we assessed the
transcriptional distribution of the ten genes across the peripheral immune system by measuring
their expression levels on isolated neutrophils, monocytes, B-lymphocytes, CD-4+ T-lymphocytes,
CD-8+ T-lymphocytes, and NK cells generated from the blood of healthy donors (n=3). Then, we
examined the relationship between the whole blood expression levels of the ten genes and white
blood cell counts in a cohort of acute ischemic stroke patients (n=36) and acute stroke mimics
(n=15) recruited at emergency department admission. All ten genes displayed strong patterns of
lineage-specific expression in our analysis of isolated leukocytes, and their whole blood
expression levels were correlated with white blood cell differential across the total patient
population, suggesting that many of them are likely differentially expressed in whole blood during
stroke as an artifact of stroke-induced shifts in leukocyte counts. Specifically, factor analysis
inferred that over 50% of the collective variance in their whole blood expression levels across the
patient population was driven by underlying variance in white blood cell counts alone. However,
the cumulative expression levels of the ten genes displayed a superior ability to discriminate
between stroke patients and stroke mimics over white blood cell differential, suggesting that
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additional less prominent factors influence their expression levels which add to their diagnostic
utility. These findings not only provide insight regarding this particular panel of ten genes, but also
into the results of prior stroke transcriptomics studies performed in whole blood.
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Triage; Microarray; RNA Sequencing; CBC; Complete Blood Count; PCR; NLR; Neutrophil
Lymphocyte Ratio; MLR; Monocyte Lymphocyte Ratio

Introduction

Author Manuscript

The identification of circulating biomarkers which could be used to accurately detect stroke
would allow for the development of molecular diagnostics which could better inform triage
and treatment decisions in the acute phase of care. The peripheral immune system responds
robustly to stroke, and multiple genome-wide transcriptomic studies have demonstrated that
stroke induces widespread alterations in gene expression at the level of whole blood [1–5].
Recently, our group leveraged this phenomenon to identify a blood-based RNA panel
consisting of seven upregulated genes (PLXDC2, STK3, ANTXR2, KIF1B, CD163, PDK4,
CTSZ) and three downregulated genes (GRAP, MAL, ID3) which has demonstrated the
ability to accurately detect acute ischemic stroke (AIS) in three independent patient
populations [3,6]. While this candidate biomarker panel has potential for clinical use, the
mechanisms by which its constituent genes become differentially expressed in whole blood
during stroke remain unclear.

Author Manuscript

Stroke induces rapid and pronounced changes in the complexion of the circulating leukocyte
pool. Increases in damage associated molecular signaling at the site of injury, along with
elevations in sympathetic innervation of peripheral myeloid tissue, trigger robust activation
of the innate immune system [7–9], resulting in a substantial rise in circulating monocyte
and neutrophil counts in the hours following onset [10,11]. Simultaneously, sympathetic
signaling to peripheral lymphoid organs shifts the adaptive immune system into a state of
suppression [7–9], which results in a marked reduction in circulating lymphocyte counts that
can persist for weeks post-injury [11]. Within the context of this immune response, it is
likely that these genes exhibit differential expression in whole blood during stroke as a result
of two not-necessarily distinct scenarios:

Author Manuscript

First, it is possible that these genes undergo true transcriptional modifications at the level of
individual circulating cells, and that these transcriptional changes help drive the strokeinduced shift in peripheral immune phenotype. This scenario is intriguing from the
standpoint that the stroke-induced peripheral immune response significantly influences
patient outcome, as alterations in its magnitude and duration are known to drive secondary
complications such as hemorrhagic transformation and post-stroke infection [10–15]; if
these genes are biological drivers of stroke immunopathology, it would make them
legitimate therapeutic targets which could be leveraged for immunomodulation.
Conversely, it is possible that these genes exhibit altered whole blood expression in response
to stroke simply as artifacts of the stroke-induced change in leukocyte counts. The numerous

Transl Stroke Res. Author manuscript; available in PMC 2020 February 01.

O’Connell et al.

Page 3

Author Manuscript

subpopulations of leukocytes which comprise the peripheral immune system carry
transcriptomes which are highly unique [16]. Thus, shifts in white blood cell (WBC)
differential can result in altered gene expression at the level of whole blood, even in the
absence of true transcriptional modifications at the level of individual cells [17]; this is
especially true in the case of genes which exhibit extreme transcriptional heterogeneity
across leukocyte subpopulations. If the genes in question are differentially regulated in
whole blood as a result of this scenario, they would still have diagnostic utility, however it
would be less likely that they are biological drivers of pathology.

Author Manuscript

Not only could identifying which of the aforementioned mechanisms drive the differential
expression of these genes improve their clinical utility as biomarkers by providing biological
context, but it could also produce novel insight into stroke immunopathology as a whole.
Thus, the purpose of this study was to examine the potential mechanisms by which this
previously identified ten marker panel of stroke-associated genes becomes differentially
expressed in whole blood during stroke.

Materials and Methods
Experimental Design

Author Manuscript

Peripheral venous blood samples were obtained from 36 AIS patients and 15 acute stroke
mimics at emergency department admission (Table 1). In addition, liquid biopsies were also
obtained from 3 healthy donors. In order to examine the susceptibility of the ten previously
identified stroke-associated genes to undergo altered expression in whole blood as a result of
perturbations in WBC differential, we first examined their transcriptional distribution across
numerous isolated subpopulations of leukocytes generated from healthy donor peripheral
blood. We then assessed the individual relationships between the whole blood RNA
expression levels of each of the ten genes and WBC differential across the total patient
population; factor analysis was subsequently used to estimate what proportion of variance in
their collective expression levels was attributable to WBC differential. Lastly, we compared
the ability of whole blood expression levels of the ten genes to discriminate between stroke
patients and stroke mimics to that of WBC differential alone.
Subjects

Author Manuscript

Healthy donors, AIS patents, and stroke mimics were recruited from 2011 to 2015 at Ruby
Memorial Hospital, Morgantown, WV. All AIS patients displayed definitive radiographic
evidence of vascular ischemic pathology on magnetic resonance imaging (MRI) or
computed tomography (CT) according to the criteria for diagnosis of acute ischemic
cerebrovascular syndrome (AICS) [18]. Patients admitted to the emergency department as
suspected strokes based on the overt presentation of stroke-like symptoms, but receiving a
definitive negative AICS diagnosis upon neuroradiological imaging and clinical evaluation
were identified as acute stroke mimics [18]. Discharge diagnoses of stroke mimics included
cases of seizures, complex migraines, hypertensive encephalopathy, and other non-stroke
conditions which induce neurological symptoms. All diagnoses were confirmed by an
experienced neurologist. Patients were excluded from enrolment if they received a nondefinitive AICS diagnosis, presented with evidence of hemorrhagic pathology on
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neuroradiological imaging, presented with cancer as a co-pathology, were under 18 years of
age, or arrived to the emergency department outside of 24 hours from symptom onset. Injury
severity was determined according to the National Institutes of Health stroke scale (NIHSS).
Demographic information was collected from either the subject or significant other by a
trained clinician. Procedures were approved by the institutional review boards of West
Virginia University and Ruby Memorial Hospital (IRB protocol 1410450461R001), and
written informed consent was obtained from all subjects or their authorized representatives
prior to study procedures.
Neuroradiological Imaging

Author Manuscript

CT imaging was performed on either a Toshiba Aquilion 64 or Toshiba Aquilion 320
scanner (5 mm slices acquired at 120 KVp, 250 mA). MRI imaging was performed using
either a Siemens Aera or Siemens Verio scanner (5 mm slices, 5 mm inter-slice gap,
acquired via diffusion-weighted echoplanar imaging with a B-factor of 1000 s/mm2). The
BrainLAB iPlan Neuroradiology software package (BrainLAB, Westchester, Ill) was used to
calculate infarct volume via manual tracing.
Type of cerebral infarction was classified via the four categories described by Bamford et al.
based solely on radiographic evidence of the following: anterior circulation infarct with
restricted cortical involvement (partial anterior cerebral infarction), large anterior circulation
infarct with both cortical and subcortical involvement (total anterior cerebral infarction),
small perforating artery infarction (lacunar cerebral infarction), vertebrobasilar territory
infarction (posterior cerebral infarction) [19,20].
Blood collection
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All blood sampling was performed prior to the administration of thrombolytics. Parallel
peripheral intravenous whole blood samples were collected from subjects via PAXgene RNA
tubes (Qiagen, Valencia, CA) and K2EDTA Vacutainers (Becton Dickenson, Franklin Lakes,
NJ). PAXgene RNA tubes were frozen immediately and stored at -80ºC until RNA
extraction, while K2EDTA tubes were stored at room temperature until white blood cell
differential (less than 30 minutes) or leukocyte isolation (performed immediately).
Isolation of leukocyte subpopulations
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Leukocytes were isolated from EDTA-treated blood via immuno-magnetic negative selection
(EasySep Direct, StemCell Technologies, Vancouver, BC). Neutrophils, monocytes, CD4+
T-lymphocytes, CD8+ T-lymphocytes, B-lymphocytes, and NK-cells were isolated from 4
mLs of blood per population according to the manufacture recommended protocol. Isolated
cells were rinsed once in PBS and lysed in Qiagen buffer RLT containing betamercaptoethanol, flash frozen in liquid nitrogen, and stored at −80 until RNA extraction.
RNA extraction and qRT-PCR
Whole blood RNA was extracted from PAXgene tubes via the PreAnalytiX PAXgene blood
RNA kit (Qiagen) and automated using the QIAcube system (Qiagen). RNA was isolated
from leukocyte lysates via the RNeasy Micro kit (Qiagen). Quantity and purity of isolated
RNA was determined via spectrophotometry (NanoDrop, Thermo Scientific, Waltham, MA).
Transl Stroke Res. Author manuscript; available in PMC 2020 February 01.
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cDNA was generated from purified RNA via Applied Biosystems high capacity reverse
transcription kit. For qPCR, target sequences were amplified from 10 ng of cDNA input
using sequence specific primers (Supplemental Table I) and detected via SYBR green
(PowerSYBR, Thermo-Fisher) on the RotorGeneQ (Qiagen). Raw amplification plots were
background corrected and CT values were generated via the RotorGeneQ software package.
All reactions were performed in triplicate. Transcripts of B2M, PPIB, and ACTB were
amplified as low variability references and normalization was performed using the
NORMA-gene data-driven normalization algorithm [21,22].
White blood cell differential and NMLR

Author Manuscript

Complete blood count was obtained from EDTA-treated blood via combined optical flow
cytometry and cellular impedance using an automated clinical hematology analyzer (CellDyn, Abbott Diagnostics, Santa Clara, CA). WBC differential was summarized in terms of
the neutrophil-monocyte to lymphocyte ratio (NMLR), as it provides a single variable which
can be intuitively used to infer peripheral immune status within the context of the known
shifts in WBC counts which occur in response to stroke. NMLR was calculated as the
geometric mean of absolute neutrophil and absolute monocyte count divided by absolute
lymphocyte count:
NMLR =

neutrophil count ∗ monocyte count
lymphocyte count

Statistics

Author Manuscript

All statistics were performed using R 3.3 (R project for statistical computing) [23]. Fisher’s
exact test was used for comparison of dichotomous variables, while t-test or one-way
ANOVA was used for the comparison of continuous variables where appropriate. Either
Spearman’s rho or Pearson’s r was used to assess the strength of correlational relationships
depending on level of homoscedasticity. Factor analysis was performed using the factanal()
function; prior to analysis, data were tested for sphericity and sampling adequacy via
Bartlett’s test and the Kaiser-Mayer-Olkin index. Covariance matrix hierarchical clustering
was performed using the hclust() function.

Author Manuscript

The diagnostic ability of binary classifiers was assessed via receiver operator characteristic
(ROC) using the ‘pROC’ package [24]. In the case of classification using a single variable,
ROC curves were generated directly using the roc() function. In the case of classification
using multiple variables, classification was performed using k nearest neighbors (kNN) via
the knn.cv() function of the ‘class’ package [25], and the resultant prediction probabilities
were used for receiver operator characteristic (ROC) curve generation. Statistical
comparison of area under ROC curves was performed using roc.test() function according the
non-parametric method described by DeLong et al. [26].
Sample sizes were arbitrarily determined. In the case of all statistical testing, the null
hypothesis was rejected when p<0.05. In the case of multiple comparisons, P-values were
adjusted via the Benjamini-Hochberg method [27]. The parameters of all statistical tests
performed are outlined in detail within the figure legends.
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Results
Stroke-associated genes exhibit lineage-specific expression in the peripheral immune
system

Author Manuscript

In order to examine the susceptibility of the ten previously identified stroke-associated genes
to undergo altered expression in whole blood as a result of perturbations in WBC
differential, we first examined their transcriptional distribution across numerous isolated
subpopulations of leukocytes generated from the peripheral blood of healthy donors.
Interestingly, each of the ten genes exhibited some degree of lineage-specific expression. All
seven genes which have been previously identified as being up-regulated in whole blood
during AIS were predominantly expressed on cell populations of myeloid origin.
Conversely, all three genes which have been previously identified as being downregulated in
whole blood during AIS were predominantly expressed on cells of lymphoid origin (Figure
1). In the case of several genes, the differences in expression between myeloid and lymphoid
populations were quite substantial, ranging from hundreds-fold to thousands-fold; this
extreme heterogeneity in expression suggested that the whole blood expression levels of
these genes could be dramatically influenced by shifts in white blood cell differential.
Whole blood expression levels of stroke-associated genes are strongly correlated with
WBC differential

Author Manuscript

Next, we examined the relationship between the whole blood expression levels of the ten
previously identified stroke-associated genes and WBC differential in liquid biopsies
obtained from AIS patients and stroke mimics at emergency department admission. The
expression levels of each of the seven genes which have been previously identified as being
up-regulated in whole blood during AIS were strongly positively associated with NMLR
across the total patient population. Conversely, the expression levels of all three genes which
have been previously identified as being down-regulated in whole blood during AIS were
strongly negatively associated with NMLR (Figure 2). Taken as a whole, the relationships
we observed with NMLR, along with the strong pattern of lineage-specific expression,
suggested that the whole blood expression levels of many if not all of these genes likely
serve as markers of the cellular composition of the circulating leukocyte pool, and that their
differential expression in response to stroke simply reflects a shift in WBC counts.
A majority of variance in the expression levels of stroke-associated genes is attributable to
variance in WBC counts

Author Manuscript

We then wanted to quantify what proportion of the variance in whole blood expression levels
across the ten previously identified stroke-associated genes was attributable to WBC count
alone; factor analysis was used extract the structure of latent factors underlying the
cumulative variance in expression across the ten genes, and the relationships between the
extracted factors and WBC differential was assessed across the total patient population. The
whole blood expression levels of the ten genes exhibited a high degree of intercorrelation.
Remarkably, hierarchal clustering of the genes based on the covariance in their whole blood
expression levels produced perfect clustering according to their predominant leukocyte
subpopulations of expression observed in our analysis of isolated leukocytes (Figure 3A),
further supporting the idea that the whole blood expression levels of these genes serve as a
Transl Stroke Res. Author manuscript; available in PMC 2020 February 01.
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marker of white blood cell count. The predominant factor extracted in factor analysis (Factor
1) captured 54.3% of the collective variance in whole blood expression levels across the ten
genes (Figure 3B), and exhibited a robust positive correlation with NMLR (Figure 3C);
taken together, these two pieces of information infer that potentially over half the collective
variance in the whole blood expression levels of the ten genes across the patient population
were attributable just to underlying variance in WBC count.
Stroke-associated genes exhibit superior diagnostic performance relative to WBC
differential alone

Author Manuscript

Lastly, we compared the ability of the whole blood expression levels of the ten previously
identified stroke-associated genes to discriminate between AIS patients and stroke mimics to
that of WBC alone. We observed an identical pattern of whole blood differential expression
between stroke patients and stroke mimics across the ten genes as described in our prior
work (Figure 4A), and their collective unmanipulated expression levels were able to
discriminate between groups with high levels of accuracy using kNN for classification
(Figure 4B). Expectedly, NMLR was significantly elevated in stroke patients in comparison
to stroke mimics (Figure 4A); however, NMLR displayed a statistically inferior ability to
differentiate between groups relative to the collective unmanipulated expression levels of the
ten stroke-associated genes when comparing area under ROC curve (Figure 4B).
Unsurprisingly, the predominant factor extracted from the whole blood expression levels of
the ten genes in our factor analysis displayed similar diagnostic ability as NMLR (Figure
4B). Taken together, this suggests that even though a majority of the variance in the
collective whole blood expression levels of ten genes is likely directly driven by WBC
differential, there are other factors that influence their whole blood expression levels that are
additive in terms of their diagnostic performance.

Author Manuscript

Discussion

Author Manuscript

Our group recently identified a panel of ten genes whose whole blood expression levels have
demonstrated an ability to detect ischemic stroke with high levels of accuracy [3,6]. The
goal of this study was to examine the potential mechanisms by which this ten marker panel
of genes becomes differentially regulated in whole blood in response to stroke. Collectively,
our results infer that a substantial degree of the stroke-induced differential expression
observed across the ten genes occurs as an artifact of shifts in WBC differential, and not true
transcriptional modifications at the levels of individual cells. While this does not diminish
the potential of these genes for diagnostic use, it suggests that it is unlikely that they are
biological drivers of the stroke-induced immune response. These findings not only provide
insight regarding this particular panel of ten genes, but also into the results of prior genomewide stroke transcriptomics studies performed in whole blood.
It is well established that stroke induces a rapid rise in circulating counts of myeloid cell
populations such as neutrophils and monocytes [10,11], and a simultaneous drop in counts
of lymphoid cell populations such as T and B lymphocytes [11]. Due to transcriptional
diversity existing across the leukocyte subpopulations which comprise the peripheral
immune system [16], such shifts in WBC count can alter gene expression at the level of
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whole blood, even in the absence of transcriptional changes at the cellular level [17]. All ten
previously identified stroke-associated genes exhibited some degree of expressional
heterogeneity across the leukocyte subpopulations assessed in our isolated cell analysis,
suggesting that their whole blood expression levels are sensitive to perturbations in WBC
differential. Thus, it was unsurprising to find that the whole blood expression levels of each
of the ten genes was correlated with WBC counts in AIS patients and stroke mimics at
emergency department admission. Furthermore, our factor analysis inferred that over 50% of
the cumulative variance in whole blood expression levels across the ten genes in the overall
patient population was driven by underlying variance in WBC count alone. Taken together,
our collective results (summarized in Table 2) suggest that a majority of the differential
expression observed across the ten genes in response to stroke occurs as simply as a marker
of the stroke-induced shift in the cellularity of the peripheral immune system.

Author Manuscript
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In terms of immunopathology, our findings suggest that a majority of the ten genes evaluated
in this study are unlikely to be significant biological drivers of the peripheral immune
response to stroke, as the genes which drive the response are likely to be those which exhibit
true transcriptional modifications at the cellular level. However, it is relevant to note that
there are a limited number of scenarios in which this may not hold true, such as in the case
of genes which encode for secreted proteins; the concentrations of secreted protein products
may become altered in systemic circulation and exert biological effects simply by virtue of
changes in the number of secreting cells, independently of any change in transcription or
translation at the level of the individual cells themselves. One of the ten stroke-associated
genes investigated in our analysis, CD163, encodes for a protein known as cluster of
differentiation 163 (CD163) which has the potential for secretion [28]; elevated circulating
levels of soluble CD163 have been previously reported in stroke [29], and recent studies
have implemented soluble CD163 as being mechanistically involved multiple aspects of
stroke immunopathology [29–31]. However, CD163 likely represents an exception with
regards to the ten gene panel, as a majority of its genes encode for various intracellular
proteins (Supplemental Table 2) and it is unlikely that they play a similar mechanistic role in
driving the stroke-induced peripheral immune response.

Author Manuscript

From a broader prospective, our findings highlight the limitation in trying to draw
conclusions about the mechanisms which drive stroke immunopathology using gene
expression data generated from whole blood. Without additional experimentation, it is
impossible to determine which genes are differentially expressed simply as artifacts of the
stroke-induced shift in WBC differential, and which are differentially expressed due to true
transcriptional modifications at the cellular level; the inability to make this distinction makes
the identification of pathologically relevant genes difficult. However, a majority of genomewide stroke transcriptomics investigations performed in whole blood have interpreted their
results under the assumption that all observed differential expression is a result of true
cellular alterations in transcription [1–5]. Our findings clearly infer that this assumption is
likely untrue, as it is highly likely that several genes identified as being differentially
expressed in these previous studies undergo altered expression via a similar mechanism as
the ten which we assessed in our analysis. Exploratory experiments from our laboratory
support this notion, as genes such as ARG1, NPL, and CCR7 which have been identified as
being differentially regulated in these prior investigations [1,2,5] display similar
Transl Stroke Res. Author manuscript; available in PMC 2020 February 01.

O’Connell et al.

Page 9

Author Manuscript

expressional heterogeneity within the peripheral immune system, and similar relationships
with WBC differential, as the ten genes which we focused on in this study (Supplemental
Figure 2).

Author Manuscript

Thus, it is likely that some of the conclusions generated from these previous studies
regarding the potential mechanisms which drive stroke immunopathology may be flawed.
For example, based on observations of decreased expression of CCR7 in whole blood during
stroke, it has been suggested that transcriptional inhibition of chemokine receptor 7 (CCR7)
signaling mechanistically drives the reduction lymphocyte counts observed in pathology
[5,32]. However, because CCR7 exhibits thousands-fold higher expression levels on
lymphocytes than on other leukocyte subpopulations, it is more likely that CCR7 expression
is reduced in whole blood simply as an artifact of the stroke-induced drop in lymphocyte
counts. While this is just a single example, it is representative of numerous potentially
confounded conclusions made regarding stroke immunopathology based on whole blood
transcriptomic data. It is pertinent to note that the potential confounds associated with
attempting to draw mechanistic conclusions regarding stroke immunopathology through
whole blood analysis apply not only in the case of coding mRNA as largely discussed here,
but also in the case of noncoding RNA species such as lncRNA and miRNA [33,34].
Depending on the research question, future studies employing transcriptional profiling of the
peripheral immune system to explore stroke immunopathology may want to avoid such
confounds by analyzing isolated leukocyte subpopulations, or ideally, single cells.
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While our results suggest that it is unlikely that a majority of the ten genes which we
assessed in our investigation are biological drivers of stroke immunopathology, it does not
diminish their potential clinical usefulness as biomarkers. Despite the fact that a substantial
proportion of the collective variance in whole blood expression levels across the ten genes
was likely driven by underlying variance in WBC count as captured by NMLR, the
cumulative expression levels of the ten genes displayed a significantly greater ability to
discriminate between AIS patients and stroke mimics relative to NMLR alone. This suggests
that there are other factors that influence the whole blood expression levels of the genes not
explainable via NMLR which are additive in terms of their diagnostic performance. Most
probable of these factors are stroke-induced changes in WBC counts not captured by
NMLR, such as shifts in the ratios of more finite leukocyte populations such as Tlymphocytes and B-lymphocytes within the predominate leukocyte lineages. In the case of
some of the genes, these factors could also include modest stroke-induced modifications in
cellular transcription which drive a minority of the collective variance across the panel as a
whole, but nonetheless impart some diagnostic power.
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By providing improved understanding of the mechanisms which drive the differential
expression of the stroke-associated genes assessed in our analysis, our findings add to their
potential value as a biomarker panel by imparting biological context which will allow for
improved clinical interpretability in the scenario that real world implementation is realized.
Most importantly, our findings provide insight regarding situations which are most likely to
yield erroneous tests. For example, due to the likelihood that a substantial proportion of the
variance in gene expression levels across the panel is driven by WBC count, patients
presenting with infectious disease at the time of stroke evaluation may be more prone to
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false-positive results. Conversely, patients being evaluated hyper-acutely with regards to
time of symptom onset may be more prone to false-negative results, as the shifts in WBC
count induced by stroke become magnified the longer pathology progresses [12]. Additional
investigation into the aforementioned scenarios could be useful in shaping future
recommendations for clinical use.
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It is important to note that this study was not without limitations. For example, our
conclusion that stroke-induced shifts in WBC counts substantially drive the differential
expression of the investigated genes was based largely on associative data; however, we feel
that the overall pattern of associations which we observed across the experiments
overwhelmingly supported this interpretation. It could also be argued that performing our
analysis of isolated leukocytes using cells harvested from healthy donors as opposed to cells
harvested from stroke patients reduced the pathological relevance of our findings; however,
we feel it is highly unlikely that the overall transcriptional distributions of the analyzed
genes would look dramatically different in stroke patients in comparison to heathy donors,
as the patterns of expression which we observed across the leukocyte subpopulations were
highly distinct and extremely consistent across all analyzed subjects.

Author Manuscript

Collectively, our results provide clarity regarding the mechanisms by which the ten
previously identified stroke-associated genes explored in our analyses become differentially
regulated in whole blood during stroke, information which will prove useful if these genes
are to be investigated further for biomarker-based stroke detection. More broadly, our
findings provide valuable insight regarding the influence of stroke-induced shifts in
leukocyte counts on whole blood RNA expression, and highlight the potential pitfalls
associated with attempting to draw conclusions about the biologic drivers of stroke
immunopathology using expression data generated from whole blood.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Transcriptional distribution of stroke-associated genes across the peripheral immune
system

Expression levels of the ten stroke-associated genes on isolated leukocyte subpopulations
generated from the peripheral blood of one male and two female healthy donors. Expression
levels are presented as fold difference relative to the subpopulation of lowest detection, and
were statistically compared via one-way ANOVA. P-values were adjusted via the BenjaminiHochberg method to account for multiple comparisons. Arrowheads indicate the leukocyte
subpopulation of highest expression.
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Figure 2. Relationship between the whole blood expression levels of stroke-associated genes and
white blood cell differential

Relationship between peripheral whole blood expression levels of the ten stroke associated
genes and NMLR in AIS patients and stroke mimics at emergency department admission.
The strength and significance of relationships were testing using Spearman’s rho. P-values
were adjusted via the Benjamini-Hochberg method to account for multiple testing. A further
comprehensive analysis of the relationships between gene expression levels and absolute cell
counts can be found in Supplementary Figure 1.
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Figure 3. Analysis of latent factors which drive the expression levels of stroke-associated genes in
whole blood

Author Manuscript

(A) Covariance matrix depicting the correlations between the whole blood expression levels
of the ten stroke associated genes across the patient populations. Strength of correlations
were assessed via Pearson’s r. Hierarchical clustering indicates similarity in expression
based on covariance; the predominant leukocyte subpopulation of expression for each major
cluster of genes is indicated in the cluster dendrogram. (B) The proportion of total collective
variance in the whole blood expression levels of the ten stroke-associated genes attributable
to the significant latent factors identified via factor analysis, along with the loadings
associated with each factor. (C) The relationship between the predominate latent factor
identified in factor analysis and NMLR across the total patient population.
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Figure 4. Diagnostic performance of stroke-associated genes relative to white blood cell
differential

Author Manuscript

(A) The peripheral whole blood expression levels of the ten stroke-associated genes, the
predominant latent factor identified in factor analysis, along with NMLR, compared between
AIS patients and stroke mimics at emergency department admission. All variables were
scaled on an interval from zero to one using unity-based normalization. Intergroup
comparisons were made via two-sample two-tailed t-test and p-values were adjusted via the
Benjamini-Hochberg method to account for multiple comparisons. (B) ROC curve depicting
the collective ability of the whole blood expression levels of the ten-stroke associated genes
to discriminate between AIS patients and stroke mimics using kNN (k=3), compared that of
the predominant factor identified in factor analysis and NMLR. Areas under ROC curves
were statistically compared via the DeLong method and p-values were adjusted via the
Benjamini-Hochberg method to account for multiple comparisons.
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Clinical and demographic characteristics.
Stroke (n=36)

p

60.2 ± 17.2

73.1 ± 12.85

0.005*

bFemale n (%)

8 (53.3)

22 (61.1)

0.757

aNIHSS (mean ± SD)

5.0 ± 4.5

9.0 ± 7.6

0.064

Partial anterior cerebral infarction n (%)

-

19 (52.8)

-

Total anterior cerebral infarction n (%)

-

5 (13.9)

-

Posterior cerebral infarction n (%)

-

8 (22.2)

-

Lacunar cerebral infarction n (%)

-

4 (11.1)

-

cInfarct volume (mean ± SD)

-

29.3 ± 47.2

-

368 ± 325

438 ± 326

0.492

bFamily history of stroke n (%)

4 (26.7)

14 (38.9)

0.527

bHypertension n (%)

13 (86.7)

30 (83.3)

1.000

bDyslipidemia n (%)

10 (66.7)

16 (44.4)

0.220

bDiabetes n (%)

5 (33.3)

7 (19.4)

0.302

bPrevious stroke n (%)

4 (26.7)

7 (19.4)

0.711

bAtrial fibrillation n (%)

3 (20.0)

12 (33.3)

0.503

bMyocardial infarction n (%)

5 (33.3)

10 (27.7)

0.743

bHypertension medication n (%)

13 (86.7)

25 (69.4)

0.297

bDiabetes medication n (%)

5 (33.3)

7 (19.4)

0.302

bCholesterol medication n (%)

9 (60.0)

13 (36.1)

0.135

bAnticoagulant or antiplatelet n (%)

11 (73.3)

22 (61.1)

0.527

bCurrent smoking n (%)

1 (6.70)

8 (22.2)

0.251

aAge (mean ± SD)

a,dTime from onset to blood draw (mean ± SD)
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Mimic (n=15)

a

Statistical comparison via two-sample two-tailed t-test;

b

Statistical comparison via 2x2 Fisher’s exact test;

c

Measured in cubic centimeters;

d

Measured in minutes
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Summary of findings.

Author Manuscript

Change in whole blood
expression during AIS

Predominant leukocyte
subpopulation of expression

Change in circulating
leukocyte subpopulation
count during AISa

Correlation between
whole blood expression
and NMLR

PLXDC2

▲

Myeloid (Neutrophil)

▲

+

STK3

▲

Myeloid (Neutrophil)

▲

+

ANTXR2

▲

Myeloid (Neutrophil)

▲

+

KIF1B

▲

Myeloid (Neutrophil)

▲

+

CD163

▲

Myeloid (Monocyte)

▲

+

CTSZ

▲

Myeloid (Monocyte)

▲

+

PDK4

▲

Myeloid (Monocyte)

▲

+

GRAP

▼

Lymphoid (B-lymphocyte)

▼

−

MAL

▼

Lymphoid (T-lymphocyte)

▼

−

ID3

▼

Lymphoid (B-lymphocyte)

▼

−

Gene

a

As reported in Vogelgesang et al. 2008 [11]
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